Table 3.
Logistic regression model of the probability of treatment discontinuation
| Estimated OR | 95% CI | P-value | |
|---|---|---|---|
| Unadjusted model | |||
| CsA (ref OTX-101) | 1.41 | (1.24 to 1.61) | < 0.001† |
| LFT (ref OTX-101) | 1.01 | (0.89 to 1.14) | 0.917 |
| Adjusted model | |||
| CsA (ref OTX-101) | 1.35 | (1.16 to 1.57) | < 0.001† |
| Age > 64 (ref ≤ 64), years | 1.27 | (1.07 to 1.51) | 0.007† |
| Quan-CCI | 0.98 | (0.94 to 1.02) | 0.343 |
| Eye-related comorbidities (ref no) | 0.90 | (0.76 to 1.08) | 0.262 |
| Insurance (ref commercial) | |||
| Employer | 0.87 | (0.66 to 1.15) | 0.336 |
| Medicaid | 0.62 | (0.47 to 0.82) | 0.001† |
| Medicare | 0.94 | (0.78 to 1.12) | 0.478 |
| LFT (ref OTX-101) | 0.97 | (0.84 to 1.12) | 0.718 |
| Age > 64 (ref ≤ 64), years | 1.15 | (0.97 to 1.37) | 0.118 |
| Quan-CCI | 0.99 | (0.95 to 1.04) | 0.788 |
| Eye-related comorbidities (ref no) | 0.85 | (0.72 to 1.01) | 0.067 |
| Insurance (ref commercial) | |||
| Employer | 0.88 | (0.69 to 1.10) | 0.259 |
| Medicaid | 0.79 | (0.62 to 1.01) | 0.060 |
| Medicare | 0.79 | (0.66 to 0.96) | 0.015† |
CI Confidence interval, CsA Cyclosporine ophthalmic emulsion 0.05%, LFT Lifitegrast ophthalmic solution 5%, OR Odds ratio, OTX-101 Cyclosporine ophthalmic solution 0.09%, Quan-CCI Quan-Charlson Comorbidity Index, ref reference
†Indicates statistical significance as based on P-value < 0.05